Is the Amacron Vaccine a Lost Opportunity?

The only nice thing is that with four or five, we had this F-486V change. That escapes a really key class of broadly neutralizing antibodies. There's the chance by having that one in the mix that folks as B cells will be able to update that class of antibodies. But you're absolutely right, I think it was a lost opportunity to roll out the vaccine a little bit sooner.

Transcript

Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!

Get the app